CIK 0001478320
- Large accelerated filer
Adaptive Biotechnologies Corp
Sign in to watch- Ticker
- ADPT
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- WA
- Entity type
- Operating
- EIN
- 270907024
- Phone
- +1 206-659-0067
- Business address
- 1165 EASTLAKE AVE E, SEATTLE, WA, 98109
- Former names
- Adaptive TCR Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $14,724,890
- in 17 filings, $14.5M under 10b5-1 plans
Net −$14,724,890. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-18 | PISKEL KYLE Chief Financial Officer | Sale | −3,115 | $13.04 | $41K | 256,725 |
| 2026-03-11 | PISKEL KYLE Chief Financial Officer | Sale | −18,672 | $13.17 | $246K | 259,840 |
| 2026-03-04 | PISKEL KYLE Chief Financial Officer | Grant or award | +61,875 | 278,512 | ||
| 2026-02-04 | PISKEL KYLE Chief Financial Officer | Exercise or conversion 10b5-1 | +2,145 | $12.14 | $26K | 218,782 |
| 2026-02-04 | PISKEL KYLE Chief Financial Officer | Sale 10b5-1 | −2,145 | $18.46 | $40K | 216,637 |
| 2026-02-04 | PISKEL KYLE Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −2,145 | 2,146 | ||
| 2026-01-12 | PISKEL KYLE Chief Financial Officer | Exercise or conversion 10b5-1 | +4,290 | $12.14 | $52K | 220,927 |
| 2026-01-12 | PISKEL KYLE Chief Financial Officer | Sale 10b5-1 | −4,290 | $18.00 | $77K | 216,637 |
| 2026-01-12 | PISKEL KYLE Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −4,290 | 4,291 | ||
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Exercise or conversion 10b5-1 | +11,980 | $6.55 | $78K | 281,323 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Exercise or conversion 10b5-1 | +3,750 | $7.80 | $29K | 285,073 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Exercise or conversion 10b5-1 | +94,384 | $12.14 | $1.1M | 379,457 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Sale 10b5-1 | −162,820 | $19.50 | $3.2M | 216,637 |
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −11,980 | 0 | ||
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −3,750 | 0 | ||
| 2025-11-28 | PISKEL KYLE Chief Financial Officer | Exercise or conversion · Stock Option (right to buy) 10b5-1 | −94,384 | 8,581 | ||
| 2025-11-17 | PISKEL KYLE Chief Financial Officer | Sale | −238 | $14.05 | $3K | 269,343 |
| 2025-05-16 | PISKEL KYLE Chief Financial Officer | Sale | −1,929 | $8.89 | $17K | 269,581 |
| 2025-05-16 | PISKEL KYLE Chief Financial Officer | Sale | −1,929 | $8.89 | $17K | 277,396 |
| 2025-05-15 | PISKEL KYLE Chief Financial Officer | Grant or award | +7,815 | 279,325 |
Page 1 of 3 · 41 trades